BIOLASE Technology, Inc. Announces Distribution Agreement With 3Shape Corporation
Published: Aug 03, 2012
IRVINE, CA--(Marketwire - August 02, 2012) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading dental laser manufacturer and distributor, today announced that it has entered a definitive five-year agreement with Copenhagen-based 3Shape Corporation, making BIOLASE a distributor of 3Shape's TRIOS® intra-oral scanning technologies for digital impression-taking solutions in the U.S. and Canada. The TRIOS next-generation digital impression solution is designed to make impression taking easier, faster, extremely detailed, and far more efficient for dentists.
Under the terms of the agreement, BIOLASE will be a non-exclusive distributor of the TRIOS system to dentists, dental specialists and dental schools.
The TRIOS digital solution, which includes a hand-held scanner, operator's control cart and intuitive software, provides potential for faster impression taking, improved accuracy and clinical results, reduced need for retakes and less adjustment and grinding. TRIOS' unique features include spray-free scanning, high accuracy optimized for an extensive range of indications, clinical scan validation, online communication with the dental lab, intuitive Smart-Touch user interfacing and more.
"Our agreement with BIOLASE provides us significant new access to the important North American market," said Henrik Vestermark, VP of Operations, 3Shape North America. "Our TRIOS digital system is quickly becoming an important and integral part of the modern high-tech dental suite. We believe the shift to digital scanning creates a paradigm shift in dental care with the benefits to dentists and patients being proven every day."
BIOLASE Chairman and CEO Federico Pignatelli said, "The TRIOS system is a major addition to BIOLASE's Total Technology Solution initiative dedicated to expanding the Company's leadership in the global dental market. Based on our research and evaluation, we believe that it is the most advanced 3D system in the industry with significant competitive advantages. The 3Shape agreement allows BIOLASE to better serve not only the periodontists, orthodontists, endodontists and oral surgeons doing complex dentistry, but also opens a new market for BIOLASE to partner with the dental labs.
"As demonstrated by our full line of advanced, state-of-the-art dental laser products, we are continuing our goal to be the leading provider of high-tech dental technologies worldwide," Pignatelli said. "Our new agreement with 3Shape is another manifestation of that goal. As with X-rays, all impression-taking will soon be completely digital thanks to technologies like the TRIOS digital system. In fact, the digitalization of dentistry is being driven 'fast forward,' propelled by continuously advanced technologies that deal with ever more complex clinical situations and support high quality restorations.
"By putting the TRIOS digital solution together with our advanced laser products and our full line of digital imaging products under our BIOLASE umbrella, we can offer dental professionals a 'one-stop shop' for a totally integrated group of devices and dental engineering services while, at the same time, driving new revenue growth in all aspects of the dental market," concluded Pignatelli.
3Shape is a Danish company specializing in the development and marketing of 3D scanners and CAD/CAM software solutions designed for the creation, processing, analysis and management of high-quality 3D data for application in complex manufacturing processes. 3Shape envisions the age of the "full digital dental lab," and its more than 130 developers provide superior innovation power toward reaching this goal. 3Shape's flexible solutions empower dental professionals through automation of real workflows, and its systems are applied in thousands of labs in more than 70 countries worldwide, putting 3Shape technologies at the peak of the market in relation to units produced per day by dental technicians.
3Shape is a privately-held company headquartered in Copenhagen, with the market's largest team dedicated to scanner and software development for the dental segment based in Denmark and Ukraine, production facilities in Poland, and Business Development and Support Offices in New Jersey and California, USA; Shanghai, China; Varese, Italy and Bogota, Colombia. For further information regarding 3Shape, please refer to www.3shapedental.com
About BIOLASE, Inc.
BIOLASE, Inc., the World's leading Dental Laser Company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate approximately 285 patented and patent pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 19,600 lasers among 16,000 customers. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, please contact:
Allen & Caron